Jefferies Financial Group Inc. Invests $595,000 in Jazz Pharmaceuticals PLC $JAZZ

Jefferies Financial Group Inc. purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $595,000.

Other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after purchasing an additional 298,815 shares in the last quarter. Capital World Investors lifted its holdings in Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after purchasing an additional 10,345 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after purchasing an additional 145,865 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $127,344,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks Research lifted near- and medium-term earnings forecasts for Jazz Pharmaceuticals, including FY2026 EPS to $21.72 from $18.70 and FY2027 EPS to $22.26 from $20.87, which suggests improving earnings power and supports a higher valuation.
• Positive Sentiment: Several quarterly estimates were also raised, including Q2 2026, Q3 2026, Q1 2027, Q3 2027, Q4 2027, and FY2028, reinforcing optimism around the company’s growth outlook.
• Positive Sentiment: The recent publication of Phase 3 HERIZON-GEA-01 results for Ziihera in The New England Journal of Medicine adds another potential catalyst by highlighting durable survival benefits in HER2+ gastroesophageal cancer. Article Title

Jazz Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:JAZZ opened at $236.49 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $243.32. The stock has a market capitalization of $14.84 billion, a P/E ratio of -11,818.59, a PEG ratio of 0.41 and a beta of 0.27. The stock has a 50-day simple moving average of $208.12 and a 200-day simple moving average of $183.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion during the quarter. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.13 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares of the company’s stock, valued at $4,446,209. The trade was a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,028 shares of company stock worth $2,522,587 over the last three months. 4.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on JAZZ shares. Barclays upped their target price on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Leerink Partners raised their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Royal Bank Of Canada raised their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Finally, Bank of America lifted their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $242.65.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.